טוען...
SUN-418 An Uncommon Case of Anti-PD1 Agent Induced Secondary Adrenal Insufficiency
Introduction - Nivolumab is a monoclonal anti-programmed cell death receptor 1(PD1) antibody approved for the treatment of unresectable or metastatic melanoma and is known to be associated with a wide spectrum of endocrinologic derangements. The objective of this report is to describe a case of symp...
שמור ב:
| הוצא לאור ב: | J Endocr Soc |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Endocrine Society
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6553168/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-418 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|